<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01635023</url>
  </required_header>
  <id_info>
    <org_study_id>D1532C00066</org_study_id>
    <nct_id>NCT01635023</nct_id>
  </id_info>
  <brief_title>A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244</brief_title>
  <acronym>AZD6244Formula</acronym>
  <official_title>A Phase I, Single-center, Randomized, Open-label, Crossover Study to Compare the White (Current Phase II) and Blue (Planned Phase III) Capsule Formulations of AZD6244 Hyd-Sulfate in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      Study in Healthy Males to Compare the White and Blue Formulations of AZD6244.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Single-center, Randomized, Open-label, Crossover Study to Compare the White
      (Current Phase II) and Blue (Planned Phase III) Capsule Formulations of AZD6244 Hyd-Sulfate
      in Healthy Male Subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC for AZD6244 administered as a single dose of white (current Phase II) capsule formulation</measure>
    <time_frame>Measured at appropriate time-points until end of treatment peiod, approximately 24 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for AZD6244 administered as a ingle dose of white (current Phase II) capsule formulation</measure>
    <time_frame>Measured at appropriate time-points until end of treatment peiod, approximately 24 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for AZD6244 administered as a single dose of blue (planned Phase III) capsule formulation</measure>
    <time_frame>Measured at appropriate time-points until end of treatment peiod, approximately 24 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for AZD6244 administered as a single dose of blue (planned Phase III) capsule formulation</measure>
    <time_frame>Measured at appropriate time-points until end of treatment peiod, approximately 24 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>Measured throughout the study and for a7 days after the last dose, approximately 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC for AZD6244 administered as a single dose of oral solution formulation</measure>
    <time_frame>Measured at appropriate time-points until end of treatment peiod, approximately 24 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for AZD6244 administered as a single dose of oral solution formulation</measure>
    <time_frame>Measured at appropriate time-points until end of treatment peiod, approximately 24 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>AZD6244 white capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75mg AZD6244 white (current Phase II) capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD6244 blue capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75mg AZD6244 blue (planned Phase III) capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD6244 solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>35mg AZD6244 oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6244 Dosing Period 1</intervention_name>
    <description>Treatment A, B, or C depending on randomization assignment</description>
    <arm_group_label>AZD6244 white capsule</arm_group_label>
    <arm_group_label>AZD6244 blue capsule</arm_group_label>
    <arm_group_label>AZD6244 solution</arm_group_label>
    <other_name>AZD6244</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6244 Dosing Period 2</intervention_name>
    <description>Treatment A, B, or C depending on randomization assignment</description>
    <arm_group_label>AZD6244 white capsule</arm_group_label>
    <arm_group_label>AZD6244 blue capsule</arm_group_label>
    <arm_group_label>AZD6244 solution</arm_group_label>
    <other_name>AZD6244</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6244 Dosing Period 3</intervention_name>
    <description>Treatment A, B, or C depending on randomization assignment</description>
    <arm_group_label>AZD6244 white capsule</arm_group_label>
    <arm_group_label>AZD6244 blue capsule</arm_group_label>
    <arm_group_label>AZD6244 solution</arm_group_label>
    <other_name>AZD6244</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6244 Dosing Period 4</intervention_name>
    <description>Treatment B</description>
    <arm_group_label>AZD6244 blue capsule</arm_group_label>
    <other_name>AZD6244</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers aged 18 to 55 BMI between 18 and 30 kg/m2 inclusive and weigh
             at least 50 kg and no more than 100 kg, inclusive Calculated creatinine clearance
             (CRCL) greater than 50 mL/min usin gthe Cockcroft-Gault formula

        Exclusion Criteria:

          -  History or presence of gastrointestinal, hepatic, or renal disease or any other
             condition know to interfere with absorption, distribution, metabolism, or exertion of
             drugs.

          -  Any positive result on screening for serum hepatitis B surface antigen, hepatitis C
             antibody, or HIV.

          -  Any clinically important abnormalities in rhythm, conduction, or morphology of the
             resting dECG and any clinically important abnormalities in the 12-lead dECG that
             suggest a cardiac, metabolic or other noncardiac condition.

          -  Current or past history of central serous retinopathy or retinal vein thrombosis,
             intraocular pressure greater than 21 mmHg or uncontrolled glaucoma Known or suspected
             history of drug abuse, current smokes or those who have smoked or used
             nicotine-containing products within the previous 3 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Smith, MEDICAL SCIENCE DIRECTOR</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eleanor Lisbon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Reseatch Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2012</study_first_submitted>
  <study_first_submitted_qc>July 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2012</study_first_posted>
  <last_update_submitted>October 24, 2012</last_update_submitted>
  <last_update_submitted_qc>October 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>AZD6244</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>AUC</keyword>
  <keyword>Cmax</keyword>
  <keyword>tmax</keyword>
  <keyword>AUC(0-t)</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

